NYSE: A
Agilent Technologies
Health Care · Laboratory Analytical Instruments
52-week range
$108.35$182.99
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$39.0B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2016, ended Oct 31, 2016 | $14.0B |
| FY2017, ended Oct 31, 2017 | $22.0B |
| FY2018, ended Oct 31, 2018 | $20.6B |
| FY2019, ended Oct 31, 2019 | $23.5B |
| FY2020, ended Oct 31, 2020 | $31.3B |
| FY2021, ended Oct 31, 2021 | $47.6B |
| FY2022, ended Oct 31, 2022 | $41.0B |
| FY2023, ended Oct 31, 2023 | $30.3B |
| FY2024, ended Oct 31, 2024 | $37.2B |
| FY2025, ended Oct 31, 2025 | $41.5B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $39.0B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$7.37B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2016, ended Oct 31, 2016 | $4.20B |
| FY2017, ended Oct 31, 2017 | $4.47B |
| FY2018, ended Oct 31, 2018 | $4.91B |
| FY2019, ended Oct 31, 2019 | $5.16B |
| FY2020, ended Oct 31, 2020 | $5.34B |
| FY2021, ended Oct 31, 2021 | $6.32B |
| FY2022, ended Oct 31, 2022 | $6.85B |
| FY2023, ended Oct 31, 2023 | $6.83B |
| FY2024, ended Oct 31, 2024 | $6.51B |
| FY2025, ended Oct 31, 2025 | $6.95B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $7.37B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2016, ended Oct 31, 2016 | $462M | $654M |
| FY2017, ended Oct 31, 2017 | $684M | $713M |
| FY2018, ended Oct 31, 2018 | $316M | $910M |
| FY2019, ended Oct 31, 2019 | $1.07B | $866M |
| FY2020, ended Oct 31, 2020 | $719M | $802M |
| FY2021, ended Oct 31, 2021 | $1.21B | $1.30B |
| FY2022, ended Oct 31, 2022 | $1.25B | $1.02B |
| FY2023, ended Oct 31, 2023 | $1.24B | $1.47B |
| FY2024, ended Oct 31, 2024 | $1.29B | $1.37B |
| FY2025, ended Oct 31, 2025 | $1.30B | $1.15B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $1.44B | $1.27B |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$1.76B
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2016, ended Oct 31, 2016 | $2.29B |
| FY2017, ended Oct 31, 2017 | $2.68B |
| FY2018, ended Oct 31, 2018 | $2.25B |
| FY2019, ended Oct 31, 2019 | $1.38B |
| FY2020, ended Oct 31, 2020 | $1.44B |
| FY2021, ended Oct 31, 2021 | $1.48B |
| FY2022, ended Oct 31, 2022 | $1.05B |
| FY2023, ended Oct 31, 2023 | $1.59B |
| FY2024, ended Oct 31, 2024 | $1.33B |
| FY2025, ended Oct 31, 2025 | $1.79B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $1.76B |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$3.95B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2016, ended Oct 31, 2016 | $1.89B |
| FY2017, ended Oct 31, 2017 | $2.00B |
| FY2018, ended Oct 31, 2018 | $1.79B |
| FY2019, ended Oct 31, 2019 | $2.40B |
| FY2020, ended Oct 31, 2020 | $2.36B |
| FY2021, ended Oct 31, 2021 | $2.73B |
| FY2022, ended Oct 31, 2022 | $2.77B |
| FY2023, ended Oct 31, 2023 | $2.73B |
| FY2024, ended Oct 31, 2024 | $3.39B |
| FY2025, ended Oct 31, 2025 | $3.35B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $3.95B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Down 12.4% since 2016.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.282M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2016, ended Oct 31, 2016 | 322M |
| FY2017, ended Oct 31, 2017 | 323M |
| FY2018, ended Oct 31, 2018 | 319M |
| FY2019, ended Oct 31, 2019 | 310M |
| FY2020, ended Oct 31, 2020 | 307M |
| FY2021, ended Oct 31, 2021 | 302M |
| FY2022, ended Oct 31, 2022 | 296M |
| FY2023, ended Oct 31, 2023 | 293M |
| FY2024, ended Oct 31, 2024 | 286M |
| FY2025, ended Oct 31, 2025 | 283M |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | 282M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.Net: $249M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2016, ended Oct 31, 2016 | $434M | $58.0M |
| FY2017, ended Oct 31, 2017 | $194M | $60.0M |
| FY2018, ended Oct 31, 2018 | $422M | $70.0M |
| FY2019, ended Oct 31, 2019 | $723M | $72.0M |
| FY2020, ended Oct 31, 2020 | $469M | $83.0M |
| FY2021, ended Oct 31, 2021 | $788M | $110M |
| FY2022, ended Oct 31, 2022 | $1.14B | $125M |
| FY2023, ended Oct 31, 2023 | $575M | $111M |
| FY2024, ended Oct 31, 2024 | $1.15B | $129M |
| FY2025, ended Oct 31, 2025 | $425M | $128M |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $380M | $131M |
Revenue (TTM)
$7.37B
+8.6% YoY
Net income (TTM)
$1.44B
+18.0% YoY
Cash
$1.76B
+14.5% YoY
Total debt
$3.95B
+15.8% YoY
Valuation
At current price- Market Cap
- $49.3B
- P/E
- 34.2×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 6.7×
- Price / Book
- 6.7×
- EV / EBITDA
- 27.0×
Growth
Trailing 12 months- Revenue (TTM)
- $7.37B
- Revenue Growth YoY
- 8.6%
- Revenue CAGR 3Y
- 0.5%
- Revenue CAGR 5Y
- 5.4%
- EPS Growth YoY
- 18.5%
- Net Income Growth YoY
- 18.0%
Profitability
Trailing 12 months- Gross Margin
- 53.8%
- Operating Margin
- 22.2%
- Net Margin
- 19.5%
- FCF Margin
- 17.2%
- Return on Equity
- 21.0%
Earnings
Trailing 12 months- Net Income
- $1.44B
- EPS (diluted)
- $5.07
- EBITDA
- $1.91B
- Operating Income
- $1.64B
Balance Sheet
As of Jul 31, 2026- Cash and cash equivalents
- $1.76B
- Total Debt
- $3.95B
- Net Debt
- $2.19B
- Total Assets
- $14.0B
- Total Liabilities
- $6.60B
- Shareholders' Equity
- $7.36B
Cash Flow
Trailing 12 months- Operating Cash Flow
- $1.61B
- Capital Expenditure
- $342M
- Free Cash Flow
- $1.27B
Dividends and risk
Last 12 months- Dividend Yield
- 0.6%
- Dividend / Share
- $1.02
- Beta (5Y)
- 1.21
Every ratio is calculated from the company’s reported figures.
Strength
Revenue is up 8.6% year over year, at $7.37B.
Note
Net margin of 19.5% over the last 12 months.
Note
Net debt of $2.19B is 1.1× EBITDA, a manageable load.
Strength
Turns 17.2% of revenue into free cash flow.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-K for the fiscal year ended Oct 31, 2025 · filed Dec 22, 2025
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2024 · 10-K58Nothing notable
58Nothing notable
10-K for the fiscal year ended Oct 31, 2024
Filed Dec 20, 2024 · Read the filing on EDGAR
- Revenue fell 5% to $6,510 million as drug-industry customers kept cutting equipment budgets, but net income rose 4% to $1,289 million thanks to cost cuts and higher interest income.
- Operating profit in the two instrument segments, which make up about three-quarters of sales, fell 16% and 12%. The CrossLab services segment grew profit 13%.
- Agilent bought BIOVECTRA for $915 million to expand contract drug manufacturing, funded partly by $1.2 billion of new bonds. It also bought back $1.15 billion of its own shares.
- A new restructuring cuts about 500 jobs to save about $100 million a year. Management expects a gradual, steady recovery.
Business momentum
Mixed
“Agilent's net revenue of $6,510 million in 2024 decreased 5 percent when compared to 2023.”
Outlook
Positive
“While customer capital budgets continue to be constrained, we anticipate a gradual and steady recovery in the short-term.”
Financial stress
Low
“Net cash provided by operating activities was $1,751 million in 2024 compared to net cash provided of $1,772 million in 2023”
Tone against the previous report
About the same
Red flags
None found in this report.
Positives
Services business keeps growing
“Income from operations in 2024 increased by $61 million or 13 percent when compared to 2023 on a revenue increase of $76 million.”
Cost cuts lifted margins
“When completed, the restructuring program is expected to result in the reduction of approximately $100 million in annual cost of sales and operating expenses”
Strong cash generation pays for large shareholder returns
“During the year ended October 31, 2024, we repurchased and retired 8.4 million shares for $1,150 million, excluding excise taxes, under this authorization.”
Concerns
Main instrument segment profit fell sharply
“Income from operations in 2024 decreased by $172 million or 16 percent when compared to 2023 on a revenue decrease of $295 million.”
Drug-industry customers keep cutting equipment spending
“Overall, product revenue declined due to our customers' continued capital expenditure pressures and mostly impacted the pharmaceutical market”
Continued weakness in China
“The revenue decline in Asia Pacific was driven by lower demand in China within our liquid chromatography, liquid chromatography mass spectrometry, gas chromatography mass spectrometry and spectroscopy businesses”
New risks since the previous report
Integrating the $915 million BIOVECTRA acquisition
“Management excluded BIOVECTRA from its assessment of the effectiveness of the company's internal control over financial reporting as of October 31, 2024.”
Spare factory capacity from the drug-manufacturing expansion
“Our anticipated capital expenditures for fiscal year 2025 will be approximately $450 million.”
Risks from using artificial intelligence
“The use of AI, particularly generative AI, presents opportunities as well as risks that could negatively impact the business.”
Global 15% minimum tax rules
“We are currently evaluating the potential impacts that Pillar Two may have on future periods”
Biggest risks named
- Customers cutting equipment and research spending
- Weak demand in China and US-China trade tensions
- Integrating acquisitions, including BIOVECTRA
- Changes to tax laws, global minimum tax and Singapore tax incentives
- Stricter regulation of diagnostics, such as the FDA and EU IVDR rules
Artificial intelligence in this business: Mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | −3 | |
| Outlook | +3 | |
| Tone against the previous report | 0 | |
| Financial stress | 0 | |
| Red flags | 0 | |
| New risks | −2 | |
| Score | 58 | |
Written by AI (Claude Opus 5.5) from the report’s text. 13 of 13 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-K | Dec 22, 2025 | Pro | |||
| 10-K | Dec 20, 2024 | 58 | Mixed | None | |
| 10-K | Dec 20, 2023 | 45 | Weakening | 1 medium | |
| 10-K | Dec 21, 2022 | 67 | Improving | None | |
| 10-K | Dec 17, 2021 | 75 | Strong improvement | None | |
| 10-K | Dec 18, 2020 | 55 | Mixed | 1 medium | |
| 10-K | Dec 19, 2019 | 67 | Improving | None | |
| 10-K | Dec 20, 2018 | 47 | Sharp deterioration | 1 minor | |
| 10-K | Dec 21, 2017 | 69 | Strong improvement | None | |
| 10-K | Dec 20, 2016 | 67 | Improving | 2 minor |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q3 FY2026 (period ended Jul 31, 2026), filed Sep 1, 2026. View filings on SEC EDGAR